International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee by Ambros, P F et al.
International consensus for neuroblastoma molecular diagnostics:
report from the International Neuroblastoma Risk Group (INRG)
Biology Committee
PF Ambros*,1, IM Ambros*,1, GM Brodeur
2, M Haber
3, J Khan
4, A Nakagawara
5, G Schleiermacher
6,
F Speleman
7, R Spitz
8, WB London
9, SL Cohn
10, ADJ Pearson
11 and JM Maris*,2
1CCRI, Children’s Cancer Research Institute, Vienna, Austria;
2Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, University of
Pennsylvania School of Medicine, PA, USA;
3Children’s Cancer Institute Australia, Sydney, Australia;
4National Cancer Institute, Bethesda, MD, USA;
5Chiba
Cancer Center Research Institute, Japan;
6Institut Curie, Paris, France;
7Centre for Medical Genetics, Ghent, Belgium;
8University of Cologne, Germany;
9Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, USA;
10The University of Chicago, Chicago, IL, USA;
11Section
of Paediatrics, Institute of Cancer Research and Royal Marsden Hospital, Surrey, UK
Neuroblastoma serves as a paradigm for utilising tumour genomic data for determining patient prognosis and treatment allocation.
However, before the establishment of the International Neuroblastoma Risk Group (INRG) Task Force in 2004, international
consensus on markers, methodology, and data interpretation did not exist, compromising the reliability of decisive genetic markers
and inhibiting translational research efforts. The objectives of the INRG Biology Committee were to identify highly prognostic genetic
aberrations to be included in the new INRG risk classification schema and to develop precise definitions, decisive biomarkers, and
technique standardisation. The review of the INRG database (n¼8800 patients) by the INRG Task Force finally enabled the
identification of the most significant neuroblastoma biomarkers. In addition, the Biology Committee compared the standard operating
procedures of different cooperative groups to arrive at international consensus for methodology, nomenclature, and future directions.
Consensus was reached to include MYCN status, 11q23 allelic status, and ploidy in the INRG classification system on the basis of an
evidence-based review of the INRG database. Standardised operating procedures for analysing these genetic factors were adopted,
and criteria for proper nomenclature were developed. Neuroblastoma treatment planning is highly dependant on tumour cell
genomic features, and it is likely that a comprehensive panel of DNA-based biomarkers will be used in future risk assignment
algorithms applying genome-wide techniques. Consensus on methodology and interpretation is essential for uniform INRG
classification and will greatly facilitate international and cooperative clinical and translational research studies.
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Modern treatment strategies adjust the therapy of cancer patients
according to the predicted biological behaviour of the individual
tumour. This is especially important for neuroblastoma patients, as a
subset of neuroblastic tumours will undergo spontaneous regression
(in infants and in young children) or maturation (in children),
whereas others will rapidly progress despite intensive multimodality
therapy. This clinical heterogeneity has been known for decades
(D’Angio et al, 1971; Evans et al, 1976). However, patient age and
tumour stage alone cannot reliably predict tumour behaviour. Over
the past two decades, tumour histology, (Shimada et al,1 9 9 9 )s t a t u so f
the MYCN oncogene, (Brodeur et al, 1984; Seeger et al,1 9 8 5 ) ,a n d
tumour cell DNA content (ploidy; Look et al, 1991; Ladenstein et al,
2001) have each been shown to be independently predictive of patient
outcome in large retrospective and prospective studies. Besides these
two genetic markers, recently 11q aberrations were also included in the
INRG pretreatment risk classification (Cohn et al,2 0 0 9 ) .H o w e v e r ,t h e
optimal combination of these and additional recently described
prognostic biomarkers to build a treatment stratification algorithm has
not been determined yet. Here, we present the consensus of the INRG
Biology Committee on which markers should be used currently, on the
standardised operating procedures (SOPs; partly on the basis of
SIOPEN activities (Ambros et al, 2003)) for analysing neuroblastoma
tumour molecular diagnostics and genetic nomenclature in this
rapidly evolving field.
Genetic features of neuroblastic tumours associated with
favourable clinical behaviour
Favourable clinical behaviour of neuroblastic tumours is classically
characterised by a propensity to undergo spontaneous regression
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sor maturation without cytotoxic therapy (Figure 1). These tumours
almost always show whole chromosome gains with few, if any,
segmental chromosome aberrations and without gene amplifica-
tions. The DNA content is usually in the near-triploid (penta/
hexaploid) range (Ambros et al, 1995, 1996; Brodeur, 2003; George
et al, 2007; Mosse et al, 2007; Schleiermacher et al, 2007). This is
also the case for the neuroblastic/ganglionic cell population in
Schwann cell stroma-rich tumours, whereas the Schwann cell
population itself has a diploid DNA content (Ambros et al, 1996;
Bourdeaut et al, 2008).
Although tumour cell hyperdiploidy (usually near-triploid DNA
content) is frequently associated with spontaneous maturation
(Ambros et al, 1996) and possibly also with spontaneous regression,
this ploidy level alone cannot guarantee benign tumour behaviour
as near-triploid tumours may also have segmental chromosomal
aberrations (i.e., gains or losses of only parts of chromosomes)
and MYCN amplification, which can lead to clinically aggressive
behaviour.
Genetic features of neuroblastic tumours associated with
unfavourable clinical behaviour
Neuroblastomas with an unfavourable clinical behaviour (Figure 1)
have a high propensity for locally invasive growth and widespread
metastatic dissemination through the lymphatic and haemato-
genous systems. These tumours frequently show segmental
aberrations and high-level amplification of the MYCN locus is
detected in a substantial subset (Schwab et al, 1983; Brodeur et al,
1984; Seeger et al, 1985). MYCN amplification has been shown to
be strongly associated with rapid tumour progression and poor
prognosis in patients of all ages, with any stage of disease (Brodeur
et al, 1984; Seeger et al, 1985; Ambros et al, 1995; Perez et al, 2000).
As expected, MYCN amplification was also highly predictive of
worse outcome in the INRG cohort of patients (Cohn et al, 2009).
Frequently, adjacent or more distantly located genes, such as
DDX1, NAG, and ALK, are coamplified with MYCN, but
amplification events in the absence of MYCN amplification are
rare. Whether these coamplifications have a prognostic impact
awaits clarification (Manohar et al, 1995; Squire et al, 1995; George
et al, 1997; De Preter et al, 2002; Weber et al, 2004).
Although MYCN status is central to the risk stratification
systems in all cooperative clinical trial groups, it is important to
emphasise that the majority of metastatic neuroblastomas do not
show amplification of this oncogene (see also Figure 1). Other
chromosomal aberrations (and a diploid DNA content) have been
assumed to predict unfavourable tumour behaviour, including
deletion at the chromosomal region 1p36.3 or 11q23, (Maris et al,
1995; Caron et al, 1996b; Attiyeh et al, 2005) as well as unbalanced
gain of the long arm of chromosome 17 (17q21 to 17qter; Caron,
1995; Bown et al, 1999; Spitz et al, 2003). In addition, some studies
have shown that deletions on chromosome 3p, 4p, 9p, and 12p also
have prognostic significance (Caron et al, 1996a; Thompson et al,
2001; Schleiermacher et al, 2007). As 11q deletions are inversely
associated with MYCN amplification, this aberration has emerged
as a powerful biomarker of outcome in cases without MYCN
amplification (Attiyeh et al, 2005). Statistical analysis of the
INRG database has confirmed this finding, and on the basis of
these studies, 11q status has been included as a prognostic
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Figure 1 Biological pathways and genetic features in neuroblastic tumours. Tumour cell ploidy (grey columns) can be used to subdivide neuroblastoma
tumours into two broad groups (separated by the long punctuated line). Although the ploidy subgroups roughly correspond to the biologic subgroups
(aggressive neuroblastomas marked by a red background – either with MYCN amplification in dark red and separated by a short punctuated line from
neuroblastomas without MYCN amplification vs less aggressive behaving neuroblastomas indicated by a green background), they do not totally match.
Although aggressive near-triploid neuroblastomas (in red below the long punctuated line) have been observed, it is less clear if ‘benign’ diploid
neuroblastomas without any structural aberrations (in green above the long punctuated line) occur. ‘Benign’ clinical behaviour refers either to spontaneous
regression/maturation without any therapy or with surgery only (no cytotoxic therapy).
Table 1 Tests of association of genetic factors
MYCN
amplification
1p
aberration
11q
aberration 17q gain
Diploidy Po0.0001 Po0.0001 P¼0.1242 P¼0.3613
MNA Po0.0001 P¼0.0006* P¼0.0096
1p aberration P¼0.0613 Po0.0001
11q
aberration
Po0.0001
*Inversely associated. MNA MYCN amplification
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sTable 2a Event-free and overall survival (EFS and OS) of genetic factors by INSS stage
INSS stage 1 INSS stage 2 INSS stage 3 INSS stage 4s INSS Stage 1,2,3,4s INSS Stage 4
n (%)
5-year
EFS±s.e.
5-year
OS±s.e. n (%)
5-year
EFS±s.e.
5-year
OS±s.e. n (%)
5-year
EFS±s.e.
5-year
OS±s.e. n (%)
5-year
EFS±s.e.
5-year
OS±s.e. n (%)
5-year
EFS±s.e.
5-year
OS±s.e. n (%)
5-year
EFS±s.e.
5-year
OS±s.e.
Hyper diploid
(n¼2611)
719 (28) 93±29 9 ±1 415 (16) 88±39 6 ±2 452 (17) 82±38 6 ±3 232 (9) 86±39 2 ±3 1818 (70) 88±19 4 ±1 728 (28) 47±35 3 ±3
Diploid n¼1086) 196 (18) 90±49 6 ±2 119 (11) 84±59 0 ±5 152 (14) 65±66 6 ±6 62 (6) 77±97 7 ±9 529 (49) 80±38 4 ±3 527 (50) 31±33 6 ±3
MYCN, not
amplified
(n¼5947)
1626 (27) 93±19 8 ±1 947 (16) 85±29 7 ±1 1013 (17) 81±28 9 ±1 481 (8) 82±29 1 ±2 4067 (68) 87±19 5 ±1 1798 (31) 45±25 4 ±2
MYCN, amplified
(n¼1155)
48 (4) 50±12 76±9 39 (3) 57±12 67±11 217 (19) 45±44 8 ±4 47 (4) 41±94 5 ±9 351 (30) 46±45 3 ±4 787 (69) 21±22 5 ±2
1p normal
(n¼1659)
489 (29) 93±29 8 ±1 264 (16) 83±39 8 ±1 313 (19) 77±38 8 ±3 152 (9) 86±49 5 ±3 1218 (73) 86±19 5 ±1 430 (26) 42±35 0 ±3
1p aberration
(n¼493)
48 (10) 76±9 100 29 (6) 63±11 81±9 90 (18) 52±76 1 ±7 29 (6) 60±13 67±12 196 (40) 60±57 4 ±4 280 (57) 24±43 2 ±4
11q normal
(n¼844)
227 (27) 90±39 9 ±1 141 (17) 71±79 5 ±3 152 (18) 77±58 5 ±4 69 (8) 86±79 5 ±5 589 (70) 82±39 4 ±2 233 (28) 42±55 0 ±5
11q aberration
(n¼220)
11 (5) 73±22 91±14 11 (5) 45±34 91±16 35 (16) 51±11 75±11 8 (4) 38±30 63±38 65 (30) 51±10 79±8 153 (70) 28±64 7 ±7
17q normal
(n¼187)
36 (19) 78±99 7 ±4 22 (12) 77±12 100 47 (25) 74±78 5 ±6 15 (8) 92±11 92±11 120 (64) 78±59 2 ±3 60 (32) 40±74 6 ±7
17q gain
(n¼175)
20 (11) 95±9 100 19 (11) 51±18 84±14 16 (9) 75±13 94±7 4 (2) 100 100 59 (34) 76±89 3 ±5 104 (59) 24±63 8 ±7
Table 2b Event-free and overall survival (EFS and OS) of genetic factors, by age and primary tumour site at diagnosis
Age o547 days Age 4 547 days Adrenal primary tumour site
Non-adrenal primary tumour
site
n (%)
5-year
EFS±s.e.
5-year
OS±s.e. n (%)
5-year
EFS±s.e.
5-year
OS±s.e. n (%)
5-year
EFS±s.e.
5-year
OS±s.e. n (%)
5-year
EFS±s.e.
5-year
OS±s.e.
Hyper diploid (n¼2611) 1816 (70) 88±19 5 ±1 795 (30) 48±35 4 ±3 1023 (39) 73±27 8 ±2 1473 (56) 78±28 5 ±1
Diploid (n¼1086) 425 (39) 70±47 5 ±4 661 (61) 46±35 0 ±3 489 (45) 49±45 4 ±3 556 (51) 60±36 4 ±3
MYCN, not amplified (n¼5947) 3657 (61) 88±19 5 ±1 2290 (39) 51±16 0 ±1 2439 (41) 69±17 6 ±1 3265 (55) 77±18 6 ±1
MYCN, amplified (n¼1155) 404 (35) 36±34 1 ±3 751 (65) 26±23 0 ±2 732 (63) 27±23 3 ±2 384 (33) 33±43 7 ±4
1p normal (n¼1659) 1095 (66) 88±19 6 ±1 564 (34) 49±35 9 ±3 751 (45) 71±27 8 ±2 881 (53) 77±28 8 ±2
1p aberration (n¼493) 185 (38) 57±56 5 ±5 308 (62) 26±33 8 ±4 323 (66) 33±44 4 ±4 157 (32) 48±55 8 ±5
11q normal (n¼844) 510 (60) 83±39 3 ±2 334 (40) 46±45 7 ±4 359 (43) 64±47 2 ±4 451 (53) 73±38 5 ±3
11q aberration (n¼220) 63 (29) 61±11 85±8 157 (71) 26±54 7 ±6 126 (57) 34±65 2 ±7 93 (42) 35±96 3 ±9
17q normal (n¼187) 104 (56) 80±59 2 ±3 83 (44) 44±65 3 ±6 74 (40) 60±76 5 ±7 105 (56) 67±68 2 ±5
17q gain (n¼175) 65 (37) 68±98 3 ±7 110 (63) 27±54 1 ±6 116 (66) 37±75 1 ±7 53 (30) 53±96 7 ±9
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Molecular Diagnosticscriterion in the INRG classification system. (Cohn et al, 2009).
Recent publications clearly show the potential of comprehensive
genome-wide approaches to further refine the prognostic accuracy
of somatically acquired chromosomal alterations, (Vandesompele
et al, 2005; Michels et al, 2007; Mosse et al, 2007; Schleiermacher
et al, 2007; Tomioka et al, 2008). These studies have shown that
in tumours without MYCN amplification, segmental chromosome
aberrations are associated with clinically aggressive disease. These
findings have been extended in a series of 493 MYCN amplified and
non-amplified neuroblastomas; in tumours with only whole-
chromosome copy number variations, there were no disease-related
deaths. In contrast, the presence of segmental alterations (see
Table 3) with or without MYCN amplification was the strongest
predictor of relapse (Janoueix-Lerosey et al,2 0 0 9 ) .
Tumour cell ploidy
The majority of tumours have a hyperdiploid (near-triploid or
penta/hexaploid) DNA content, whereas less than half of
neuroblastic tumours are diploid (Look et al, 1984; Kaneko et al,
1987). Locoregional tumours are commonly hyperdiploid; diploidy
is more common in advanced-stage tumours. A number of studies
have shown that in patients o18 months of age with metastatic
disease, hyperdiploidy in combination with a non-amplified
MYCN gene and the lack of specific segmental chromosome
aberrations (such as 11q deletion) are predictive of a favourable
outcome (George et al, 2005; Schleiermacher et al, 2007). However,
in patients o18 months of age with metastatic disease with
diploid, MYCN non-amplified tumours have a statistically
significantly worse outcome.
EVALUATION OF GENOMIC MARKERS IN THE INRG
ANALYTIC COHORT
Relationship of genetic aberrations
In the INRG analytic cohort (n¼8800; see Cohn et al (2009) for
details), 29% were diploid, 16% were MYCN amplified, 21% had an
11q aberration, 23% had a 1p aberration, and 48% had a 17q gain.
Statistically significant associations of genetic factors were
identified (Table 1). 11q aberration was associated with 17q gain
(Po0.0001) and inversely associated with MYCN amplification
(P¼0.0006), but 11q aberration was not associated with diploidy
or 1p aberration. Diploidy and 17q gain were not associated, but all
other pair-wise comparisons were highly statistically significant
(Po0.01).
Outcome by clinical and genetic subgroups
In the survival-tree regression approach of Cohn and Pearson et al
(2009), patients were clustered into meaningful pretreatment
groups that were homogeneous in terms of outcome and
prognostic factors (clinical and biological). For the descriptive
purposes of this manuscript, the INRG analytic cohort was further
subdivided. Outcome by genetic factors vs INSS stage, age, and
primary tumour site is shown in Tables 2a, and 2b, respectively.
Within each genetic factor subgroup, the patterns of outcome
differences that have been observed in the overall population
prevailed: (a) EFS and overall survival (OS) decreased with
increasing stage (Table 2a); (b) older patients had worse outcome
than younger patients (Table 2b) and (c) patients with adrenal
primary tumour site had worse outcome than those with non-
adrenal tumour (Table 2b).
However, as shown in Table 2a, only a limited number of data
on the prognostic impact of some segmental aberrations are
available, impeding reliable interpretation of some of the data (e.g.,
17q gain in stage 1 and 4s tumours). Thus, larger data sets on
segmental aberrations are needed to allow final statements on their
prognostic impact (Table 3).
Statistical considerations
Tests of association were carried out using a w
2-test. P-values
o0.05 were considered statistically significant. For event-free
survival (EFS) analysis, time to event was defined as the time from
diagnosis until the time of first occurrence of relapse, progression,
Table 3 Consensus of genetic markers currently used for therapy stratification and proposed for future analyses
Genetic INRG risk
classification markers Techniques recommended/accepted DNA probes recommended and comments
Obligatory markers
MYCN I-FISH
PCR, aCGH, MLPA
Two colour I-FISH: BAC or other large DNA-insert clone for the MYCN gene and a clone of
similar size for a gene/locus on the long arm of chromosome 2 (e.g., LAF at 2q11);
commercially available probes should be used whenever possible
11q23 I-FISH, PCR; pan-/multigenomic techniques:
aCGH (oligo, clone or SNP based); MLPA
Ploidy Flow or static cytometry Normal cells from the same patient should be used as a diploid standard
Genetic markers to be
analysed prospectively
1p aCGH, SNP arrays, MLPA etc. Commercially available platform preferred
2p
DDX1
NAG
ALK
3p
4p
7q
9p
12p
14q
17q
Others aCGH, SNP arrays
aCGH¼array-based comparative genomic hybridisation; BAC¼bacterial artificial chromosomes; I-FISH¼interphase fluorescence in situ hybridisation; INRG¼International
Neuroblastoma Risk Group; MLPA¼multiplex ligation-dependent probe amplification; PCR¼polymerase chain reaction; SNP¼single nucleotide polymorphism.
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ssecondary malignancy, or death, or until time of last contact if no
event occurred. For OS, time to event was defined as time until
death, or until last contact if the patient was alive. The methods of
Kaplan and Meier (1958) were used to calculate EFS and OS
estimates, with s.e. according to Peto and Peto (1972).
INTERNATIONAL CONSENSUS BY THE INRG
BIOLOGY COMMITTEE
Because of the relative rarity of neuroblastomas, and the
uniqueness of many of the molecular diagnostic factors, the INRG
Biology Committee recommended that the genetic studies required
for INRG classification be carried out in experienced laboratories,
typically central reference laboratories for the cooperative groups
(see Table 4), to guarantee high consistency and quality of results
(Ambros et al, 2003).
Consensus on the genetic markers to be currently used in
the INRG risk classification system
As reported in the study by Cohn and Pearson et al (2009)
survival-tree regression analyses of the INRG database confirmed
the prognostic significance of MYCN amplification, 11q aberra-
Table 4 Laboratories responsible for Neuroblastom Genetics
National
Group Name Institution Town Country
Australia Michelle Haber, PhD Children’s Cancer Institute Australia and COG Sydney, NSW Australia
COG Julie Gastier-Foster, PhD Nationwide Children’s Hospital Columbus, OH USA
Michael Hogarty, MD Children’s Hospital of Philadelphia Philadelphia, PA USA
Rochelle Bagatell, MD Children’s Hospital of Philadelphia Philadelphia, PA USA
Germany Frank Berthold, MD Department of Pediatric Hematology and Oncology,
University of Cologne
Cologne Germany
Jessica Theißen, PhD Department of Pediatric Hematology and Oncology,
University of Cologne
Cologne Germany
Manfred Schwab, PhD Division of Cytogenetics, German Cancer Research
Center
Heidelberg Germany
Frank Westermann, MD Division of Cytogenetics, German Cancer Research
Center
Heidelberg Germany
Freimut H Schilling, MD Department of Pediatric Oncology and Hematology,
Olgahospital
Stuttgart Germany
Sabine Stegmaier, PhD Department of Pediatric Oncology and Hematology,
Olgahospital
Stuttgart Germany
Niggli Felix, MD Department of Pediatric Oncology and Hematology Zurich Switzerland
Japan Akira Nakagawara, MD Chiba Cancer Center Research Institute Chiba Japan
Miki Ohira, MD Chiba Cancer Center Research Institute Chiba Japan
Yasuhiko Kaneko, MD Saitama Cancer Center Research Institute Saitama Japan
Junko Takita, MD Department of Pediatrics, University of Tokyo Tokyo Japan
Hajime Ohkita, MD National Center for Child Health and Development Tokyo Japan
SIOPEN Biology Peter F Ambros, PhD CCRI, Children’s Cancer Research Institute Vienna Austria
Inge M Ambros, MD CCRI, Children’s Cancer Research Institute Vienna Austria
Frank Spelemann, PhD Center for Medical Genetics-OK5, University of Ghent Ghent Belgium
Nadine Van Roy, PhD Center for Medical Genetics-OK5, University of Ghent Ghent Belgium
Ales Vicha, MD Department of Pediatric Hematology and Oncology,
Motol
Prague Czech Republic
Jean Be ´nard, MD Lab De Pharmacologie Clinique et Moleculaire, Instiut
Gustav Roussy
Villejuife-Cedex France
Alexander Valent, PhD Lab De Pharmacologie Clinique et Moleculaire, Instiut
Gustav Roussy
Villejuife-Cedex France
Je ´rome Couturier, MD Unite ´ de Cytoge ´ne ´tique oncologique, Institut Curie –
Section Me ´dicale
Paris France
Olivier Delattre, PhD Unite ´ de Cytoge ´ne ´tique oncologique, Institut Curie –
Section Me ´dicale
Paris France
Gudrun Schleiermacher, MD Unite ´ de Cytoge ´ne ´tique oncologique, Institut Curie,
Section Me ´dicale
Paris France
Marta Jeison, PhD Pediatric Hematology Oncology Department,
Schneider Children’s Medical Center of Israel
Petah Tikva Israel
Gian Paolo Tonini, PhD Translational Paediatric Oncology, National Cancer
Research Institute (IST)
Genoa Italy
Raffaella Defferrari, PhD Translational Paediatric Oncology, National Cancer
Research Institute (IST)
Genoa Italy
Katia Mazzocco, PhD Translational Paediatric Oncology, National Cancer
Research Institute (IST)
Genoa Italy
Klaus Beiske, MD Department of Pathology, Rikshospitalet Oslo Norway
Barbara Marques, PhD Centro de Gene ´tica Humana, Instituto Nacinal de
Sau ´de
Lisbon Portugal
Nicole Gross Ph.D. Recherche en Oncologie Pe ´diatrique Lausanne Switzerland
Rosa Noguera, MD Facultad de Medicina Valencia Spain
Tommy Martinsson, PhD Gahlgrenska Univ. Hospital/East, Gothenburg University Gothenburg Sweden
Deborah A. Tweddle, MD Department of Health Newcastle UK
John Lunec, PhD Northern Institute for Cancer Research Newcastle UK
Nick Bown, PhD Institute of Human Genetics Newcastle UK
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stions, and ploidy, in addition to age and stage, in different
subgroups of the INRG cohort. Table 3 includes these three
genetic markers and also those, which should be analysed
prospectively.
Tumour sampling/storing procedure and indication of the
tumour cell content
An adequate amount of tumour material (i.e., 10
7 tumour cells)
from at least two different regions of the tumour should be
obtained. In collaboration with the institutional pathologist, the
tumour cell content must be determined and recorded. The latter
is an indispensable prerequisite to avoid false results and has to be
carried out by the pathologist. A section (cryo- or paraffin) has to
be kept to each tumour piece used for genetic or expression
studies. In certain cases, interphase fluorescence in situ hybridisa-
tion (I-FISH) can be used to decide on the tumour cell number. A
tumour cell content of more than 60% is required for most
molecular studies and of more than 20% for ploidy measurement.
Differentiating/maturing tumours can have fewer tumour cells,
and therefore, the interpretation of these data need to de done with
caution. For I-FISH, a low tumour cell number can also be
sufficient, in case of numeric/structural chromosome aberrations.
Molecular studies on maturing/mature tumours, such as gang-
lioneuroblastomas or ganglioneuromas, (Ambros et al, 1996;
Brodeur, 2003) require meticulous identification of tumour and
Schwannian stromal cells, and can thus only be undertaken when
using an appropriate system (e.g., on ganglionic cells or by
microdissection, ideally on paraffin sections). In case of needle-
core biopsies, for obtaining tumour material from different areas,
an exact determination of the tumour cell content is crucial again
(Frostad et al, 1999). Interphase fluorescence in situ hybridisation
results of disseminated tumour cells in the bone marrow (Ambros
et al, 2001) can be given only if MYCN amplification is present due
to the higher error-proneness if segmental/numeric aberrations are
evaluated in mixtures of normal and tumour cells. In case of
immunological preselection and automatic relocation of DTCs
(Mehes et al, 2001), information on genetic aberrations other than
MYCN amplification can be given as well.
On account of the advent of new techniques enabling large
retrospective studies, it is essential to store frozen tumour samples
and/or extracted DNA, RNA, or protein (at  801C or in liquid
nitrogen) with exactly determined tumour cell content. Non-
neoplastic reference cells from the same patient should be stored
as well. The INRG Biology Subcommittee further emphasises the
clear need for biobanking of high quality biological materials from
neuroblastoma patients, and this must be central to the SOP of any
cooperative group for the collection of diagnostic material (Qualman
et al, 2005). For further details and recommendations, see Figure 2
and the guidelines indicated by Ambros and Ambros (2001).
Evaluation and the reporting of the MYCN gene copy status
The INRG Biology Committee agreed that MYCN status should be
evaluated in every resected neuroblastic tumour, including the
Schwann cell stroma-rich categories (Shimada et al, 1999). Recom-
mended and accepted techniques to detect structural and/or
segmental aberrations are summarised in Table 3, and recommenda-
tions concerning the evaluation and terminology are given in Tables
5–8. Interphase fluorescence in situ hybridisation is preferred
because it has a number of advantages compared with the other
techniques, most important of which is direct quality control of the
hybridization quality by the microscopist. Heterogeneous MYCN
amplification requires meticulous analysis of the tumour specimen
(Figure 3). At the present time, the prognostic significance of
heterogeneously MYCN amplified neuroblastomas is not known, but
amplification of a substantial number of tumour cells in a specimen
is still considered an ominous sign.
Evaluation and reporting of segmental genetic aberrations:
gains and losses of chromosome parts
The term ‘structural’ aberrations (also known as structural chromo-
somal instability (s)-CIN) designates any kind of chromosomal
Shock frozen
Touch preparations 
and histology
Touch preparations
and histology
A
B
A1
A3 A4
A2
The splitting of the tumour material
B1
B3 B4
B2
Shock frozen Shock frozen Shock frozen Shock frozen
Shock frozen
Figure 2 Recommendations concerning the splitting of the tumour material for resected tumours or surgical biopsies. All specimens should be
transported to the pathology laboratory as quickly as possible. From there, the snap frozen and/or OCT embedded material should then be transported
immediately to the biology lab (can be used for any type of DNA, RNA or protein work). Normal reference cells (e.g., peripheral blood) should be sent to
the reference laboratories.
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sTable 5 MYCN terms and definitions of I-FISH results
MYCN status analysed by I-FISH
Terms Description Comments
MYCN not amplified (normal
MYCN status)
A balanced ratio between the MYCN-specific signals and
the signal number of the reference probe on the
chromosome 2q arm
Neuroblastic tumours have a propensity to polyploidisation,
especially but not exclusively after therapy with the occurrence of
giant polyploid nuclei. The number of MYCN signals must not
exceed the number of reference signals on 2q (caveat: the
centromeric probe is unqualified as reference probe because of
frequent centromeric associations in such tumours). The number of
other chromosomes or the DNA index should be checked as well.
2p24 gain: The term 2p24 gain is suggested as a descriptive generic
term for MYCN signal numbers exceeding up to 4-fold
the number of reference signals on chromosomal arm
2q. This pattern could reflect either:
The use of a 2p specific probe in addition to 2q (optionally a
centromeric probe) is recommended to clarify the presence of a
chromosome 2p gain vs a restricted MYCN gain. The discrimination
could be important since a MYCN gain could indicate an ‘incipient’
MYCN amplification.
(a) 2p gain (a) a gain of short arms of chromosome 2, for example,
from unbalanced translocations involving 2p; or
Equal number of MYCN and 2p signals, exceeding 2q signals (mostly
a consistent excess of one or two MYCN and 2p signals).
(b) MYCN gain (b) a gain of the MYCN gene either chromosomally
integrated (such as duplications) or extrachromosomally
An inconsistent MYCN excess with a varying number of excess
signals is much more likely in line with MYCN gain as
extrachromosomally elements. The latter can also be found in
tumours with heterogeneous MYCN amplification.
MYCN amplification,
‘homogeneous’
More than 4-fold increase in the MYCN signal number
compared with the reference probe located on the
chromosome 2q
Details on the amplification grade (a) 44–10 times; (b) 410 times;
(c) 430 times amplification, and also on the type of amplification
either double minutes (dmin) or homogeneously staining regions
(hsr) should be given in the report.
Besides tumour cells with amplification defined as such, a proportion
of tumour cells can also show ‘MYCN gain’. However, tumour cells
without MYCN gain or amplification are extremely rare.
MYCN amplification,
‘heterogeneous’
Generic term for the coexistence of amplified as well as
non-amplified tumour cells in the same tumour
Single cells (at least two) or cell clusters or a multitude of cells with
MNA besides proven tumour cells without MNA. The terms ‘focal’
and ‘diffuse MNA’ are specifications, which, however, can only be
attributed after evaluation of the tissue sections. In case amplified
tumour cells are found in addition to non-amplified cells, a very
meticulous procedure is strongly recommended to exclude
false-positive or false negative results (see Figure 3).
(a) Focal heterogeneous MYCN
amplification
Defined as the more or less focal (one focus or several
foci – multifocal) occurrence of MYCN-amplified cells
surrounded by non-amplified tumour cells.
(b) Diffuse heterogeneous
MYCN amplification
Designates a tumour, which contains the MYCN
amplified cells in a scattered pattern besides non-MYCN
amplified tumour cells.
No result Should be specified: unclear or not interpretable;
inadequate tumour cell content; no tumour; not carried
out
I-FISH¼interphase fluorescence in situ hybridisation.
Table 6 Terms and definitions for segmental chromosome aberrations of I-FISH results
Segmental chromosome aberrations analysed by I-FISH
Terms Description Comments
Normal status Balanced ratio between the signal numbers of the
chromosomal region of interest and the reference signals on
the opposite arm of the chromosome
In the case of a 2/2 ratio, an isodisomy with a complete LOH of all loci located on
the investigated chromosome cannot be excluded. However, uniparental
isodisomies are extremely rare in NB tumours.
I-FISH imbalance
(inconclusive with
regard to LOH)
Unbalanced ratio between the signal numbers of the
chromosomal region of interest and the reference signals with
more than one signals of the chromosomal region of interest
Does not necessarily correspond to an LOH, and is therefore called inconclusive.
PCR should be performed to clarify this result. In NB tumours, imbalances
frequently, but not always, reflect LOH. Fluorescence in situ hybridisation
imbalances can also occur focally. Interphase fluorescence in situ hybridisation
imbalances should only be diagnosed if hybridisation failure can be excluded. At
least 200 cells should be evaluated.
Deletion Unbalanced ratio between the signal numbers of the
chromosomal region of interest and the reference signals with
only one signal of the chromosomal region of interest
This hybridisation pattern corresponds to an LOH. Deletions can also occur focally.
Interphase fluorescence in situ hybridisation deletion should only be diagnosed if
hybridisation failure can be excluded. At least 200 cells should be evaluated.
Gain Up to 4-fold excess of signal numbers of the chromosomal
region of interest compared with the reference signals
No result Should be specified: unclear or not interpretable; inadequate
tumour cell content; no tumour; Not carried out
I-FISH¼interphase fluorescence in situ hybridisation.
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definitions, consensus was reached to introduce the term ‘segmental’
aberrations for gains and losses of chromosome parts. In
neuroblastomas, most segmental chromosome aberrations are
unbalanced, that is, they are associated with regional losses or gains
of chromosome parts. Balanced aberrations, that is, reciprocal
translocations without losses of genetic material, are thought to be
relatively uncommon in neuroblastomas. Segmental aberrations
(such as 11q23 and 1p36.3 deletions) can be identified by a number
of techniques shown in Table 3. Currently, either I-FISH or PCR are
carried out to detect segmental aberrations, but the INRG Biology
Committee recommends array-based methods, multiplex ligation-
dependent probe amplification (MLPA) or similar techniques in the
future. The latter techniques are currently being validated (for
nomenclature (I-FISH, PCR, and MLPA), see Tables 5–8; part of the
nomenclature was developed by the SIOPEN Biology Group (for
group members, see Table 4 and Ambros et al, 2003)).
Tumour cell DNA content (ploidy)
Ploidy was analysed in the INRG cohort using the definitions
diploid (i.e., DI p1.0) vs hyperdiploid (DI 41.0) as published in
Look et al (1991). More recent data suggest that prognostic
classification may be further refined using specific ranges of DI
The INRG Biology Committee recommends recording the exact
numerical DI value for each tumour, so that clinically relevant
cutoffs for DI can be determined (for techniques see Table 3). Any
other method can be applied as long as it allows discrimination of
the diploid DNA peak. However, an unknown number of normal
cells contained in the tumour specimen under investigation,
including tumour-derived, but non-neoplastic diploid Schwann
cells are an important source of false data interpretation. Thus, the
DNA content of maturing/mature tumours, which mostly develop
from near-triploid neuroblastomas is easily misdiagnosed as
diploid.
Table 7 Terms and definitions of segmental chromosome aberrations analysed by PCR
Losses of chromosomal parts analysed by PCR
Terms Description Comments
Normal
status Similar band intensities
Allelic
imbalance
(inconclusive)
Different band intensities; The result can mean either allele disequilibrium or LOH One band is relatively weaker, when compared with the ratio of
constitutional DNA controls. Needs further clarification by FISH
(copy number of the respective chromosome has to be known) and
re-evaluation of the tumour cell content (an LOH could be masked
by a high number of normal cells). Alternatively, different PCR
probes, located on both arms (p and q) can circumvent the need for
the use of another technique.
Allele disequilibrium means an imbalance between the number of
maternal and paternal alleles (in the case of odd numbers of the
respective chromosome), but not a physical loss of alleles
Allelic loss Loss of one band One band has completely, or almost completely disappeared
No result Should be specified: unclear or not interpretable; inadequate tumour cell content
(o60%); constitutional homozygosity; no DNA; no tumour; not carried out
FISH¼fluorescence in situ hybridisation.
Table 8 Terms and definitions of chromosome aberrations analysed by MLPA
Chromosome and gene status analysed by MLPA
Terms Description Comments
Normal
status
Balanced ratio between the majority of signals (signal intensity is visualised in
the graphic representation of the MLPA results as height of the bars) of
both chromosomal arms
In the case of a balanced ratio, a uniparental isodisomy (a uniparental
isodisomy means that both chromosomes are derived from one parent.
Thus, the two chromosomes are not homologous but identical. However,
uniparental isodisomies are rare in NB tumours) with a complete LOH of all
loci located on the investigated chromosome cannot be excluded
Segmental chromosome aberration
Loss Unbalanced ratio between the signals of the chromosomal region of
interest (at least two adjacent probes) and the reference signals (at least
two probes) signals
This result could correspond to a FISH deletion that reflects an LOH, or a
FISH imbalance, which does not necessarily indicate an LOH.
Gain Unbalanced ratio (low signal excess) between the signals of the
chromosomal region of interest (at least two adjacent probes) and the
reference signals (at least two) of the chromosomal region of interest
The threshold between gain and amplification needs to be determined for
the experimental system with the help of other techniques,for example,
I-FISH
Amplification Unbalanced ratio (high signal excess) between the signals of a gene and all
other probes located on the same chromosome
The threshold between gain and amplification needs to be determined for
the experimental system with the help of other techniques, for example,
I-FISH
No result Should be specified: unclear or not interpretable; inadequate tumour cell
content; no tumour; not carried out
FISH¼fluorescence in situ hybridisation; MLPA¼multiplex ligation-dependent probe amplification; I-FISH¼interphase fluorescence in situ hybridisation.
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There is clear consensus that the use of genetic data derived from
diagnostic neuroblastoma tumours will remain central to patient
treatment planning and gain even more power. The INRG Biology
Committee addressed the issues of ongoing and future work
directed at prognostic biomarker discovery and validation, as well
as how these data sets can be leveraged to identify molecular
targets for novel therapeutics. In Table 3, 12 genetic markers to be
analysed prospectively are mentioned. Pan-genomic investigations
may help to identify additional genomic areas of interest.
DNA-based biomarkers
A number of studies suggest that the pattern of DNA-based
genomic changes is prognostic in neuroblastoma, and that whole
genome analysis should be carried out rather than a series of
individual locus-specific assays. Therefore, the INRG Biology
Subcommittee suggests using pan- or multigenomic techniques
enabling an analysis of all relevant genomic loci.
Multiplex ligation-dependent probe amplification is a PCR-
based technique that detects a large variety of segmental
aberrations and gene amplifications in a robust manner (for
technical details, see (Schouten et al, 2002). Quantification of
losses, gains, and amplifications in small amounts of DNA can be
determined, and simultaneous investigation of a large number of
loci, covering all currently known important aberrant regions
found in neuroblastomas, can be carried out in a single assay
(Villamon et al, 2008). The robust nature of the results and the
relatively low cost of the MLPA kits make this technique attractive
for routine neuroblastoma analysis.
Chip-based technologies have also been used to molecularly
classify neuroblastoma tumours (Bilke et al, 2005; George et al,
2005; Selzer et al, 2005; Spitz et al, 2006; Stallings et al, 2006;
Lastowska et al, 2007; Michels et al, 2007; Mosse et al, 2007;
Tomioka et al, 2008). Comparative genomic hybridisation has
reached a high coverage of the target sequences and become more
widely used. The advantage of single nucleotide polymorphism
(SNP)-based platforms is the simultaneous detection of physical
gains and losses and the detection of copy neutral LOH (George
et al, 2005). Still, these techniques cannot be considered as routine
techniques but as excellent tools to identify so far undetected
genomic regions of prognostic impact. The INRG Biology
Committee considers it a priority to work towards a single
Single cells or clusters of
MYCN amplified cells
Exclude contamination
Focal heterogeneous MYCN
amplification
check FISH
Diffuse heterogeneous MYCN
amplification
Check tumour cell content
local origin of the tumour,
and cytotoxic pretreatment
Multitude of MYCN amplified cells
intermingled with non-amplified cells 
Check/confirm nature
of the non-amplified cells 
Check MYCN  status
on frozen/paraffin
exclude cross hybridisation; 
insufficient hybridisation; repeat 
FISH to reach optimal 
hybridisation; 
perform other technique 
contaminated forceps, knife,
‘floating’ cells in the jars and so on,
repeat FISH without other slides; 
apply XY probes
check numeric/structural aberrations;  
check immunologic profile
scattered MYCN -amplified tumour cells
between non-amplified tumour cells
<90% of tumour cells with MYCN amplification
beside tumour cells without MYCN amplification
focal occurrence of (already 2) MYCN amplified tumour 
cells – verified in touch preparations and  sections –  
surrounded by non-MYCN-amplified tumour cells 
Heterogeneous MYCN amplification
Observation
Specification
Procedure
Finding/definition
MYCN-amplified focus/foci
between non-amplified tumour cells
Figure 3 Heterogeneous MYCN amplification and recommended procedure for the clarification of the underlying genetic pattern.
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deletions and gains, as well as MYCN amplification, and estimate
overall DNA content (ploidy), on a single platform. This has been
achieved using in-house arrays (Maris et al, 2005; Janoueix-
Lerosey et al, 2009), but a commercially available platform will be
needed to implement this or a similar technology (e.g., MLPA)
uniformly in clinical laboratories across various groups and
countries.
RNA-based biomarkers
Several groups have recently shown that genome-wide gene
expression profiling can identify differentially expressed tran-
scripts that provide reliable prognostic information (Wei et al,
2004; Ohira et al, 2005; Schramm et al, 2005; Asgharzadeh et al,
2006; Oberthuer et al, 2006; Lastowska et al, 2007; Tomioka et al,
2008). Although these studies are of outstanding quality, they each
suffer from relatively small sample sizes, necessitating preliminary
validation of proposed gene sets. In addition, there was very little
overlap in the gene sets that were identified as prognostic by each
group, so a consensus gene set, that is, predictive of outcome has
yet to be identified. International collaboration will be required to
unequivocally determine whether mRNA expression profiles, likely
focused on a representative set of genes, are a sensitive and specific
enough molecular assay to be used in the clinic, and/or if these
data are synergistic with, or override the information derived from
the assays of DNA alterations.
Molecular targets
Neuroblastoma treatment will continue to rely on risk grouping
based on tumour genomic features. Increasing attention is now
focused on utilising these data sets to discover therapeutic targets.
It stands to reason that any prognostically relevant genomic
aberration might also signal a molecular aberration that is critical
to the maintenance of the malignant phenotype, and thus can be
targeted for therapy. Regions of DNA copy number gain that result
in the overexpression of a protein that is druggable in patients
succumbing to the disease can theoretically be identified in
carefully annotated data sets in which both high quality DNA- and
RNA-based microarray data are available. Thus, a parallel focus on
therapeutic target discovery and validation will further increase the
significance of genomic efforts used in the discovery, validation, or
even clinical application phases of implementation.
CONCLUSION
Currently, neuroblastoma treatment planning is not possible
without detailed knowledge of tumour cell genomics. International
efforts were and are needed not only to identify the most
significant genetic markers but also to identify and coordinate
particularly suitable techniques for their evaluation in all patients.
For future studies, new technologies, which provide a compre-
hensive picture of the tumour cell genome are recommended.
Moreover, the INRG Biology Committee achieved consensus on
the nomenclature of genetic aberrations and developed definitions
of the terms to be used. The INRG Biology Committee is dedicated
to providing the highest possible reproducibility and reliability of
genetic markers enabling a uniform INRG classification and
forming the basis for international clinical and translational
studies. Finally, many of these recommendations apply not only
to neuroblastoma tumours but also to any tumour entity for which
genetic factors are essential for therapy decisions.
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